Jacky Vonderscher, Enyo Pharma CEO

Scoop: Af­ter hep B set­back, an Or­biMed-backed NASH biotech hunts for part­ners as it rais­es Se­ries C

Al­most four and a half years af­ter un­cloak­ing a €40 mil­lion Se­ries B, a small French biotech hopes to se­cure an­oth­er round of fi­nanc­ing to bankroll an FXR ag­o­nist in a sub­set of a field viewed as a “grave­yard of prod­ucts and com­pa­nies,” the CEO told End­points News.

The Or­biMed- and Sofinno­va-backed drug de­vel­op­er eyes a €30 mil­lion Se­ries C by the end of this year to help launch a mid-stage tri­al in a por­tion of pa­tients with non­al­co­holic fat­ty liv­er dis­ease, or NASH, who al­so have chron­ic kid­ney dis­ease, and run a Phase II study in the rare dis­ease Al­port syn­drome, a ge­net­ic con­di­tion that leads to pro­gres­sive loss of kid­ney func­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.